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702Objective: Alterations in cardiac energy and substrate metabolism play a critical role in the development and
clinical course of heart failure. We hypothesized that the cardioprotective role of the breast cancer 1, early onset
(BRCA1) gene might be mediated in part by alterations in cardiac bioenergetics.
Methods: We generated cardiomyocyte-specific BRCA1 homozygous and heterozygous knockout mice using
the Cre-loxP technology and evaluated the key molecules and pathways involved in glucose metabolism, fatty
acid metabolism, and mitochondrial bioenergetics.
Results: Cardiomyocyte-specific BRCA1-deficient mice showed reduced cardiac expression of glucose and
fatty acid transporters, reduced acetyl-coenzyme A carboxylase 2 and malonyl-coenzyme A decarboxylase
(key enzymes that control malonyl coenzyme A, which in turn controls fatty acid oxidation), and reduced car-
nitine palmitoyltransferase I, a rate-limiting enzyme for mitochondrial fatty acid uptake. Peroxisome
proliferator-activated receptor a and g and carnitine palmitoyltransferase I levels were also downregulated in
these hearts. Rates of glucose and fatty acid oxidation were reduced in the hearts of heterozygous
cardiomyocyte-restricted BRCA1-deficient mice, resulting in a decrease in the rate of adenosine triphosphate
production. This decrease in metabolism and adenosine triphosphate production occurred despite an increase
in 50-adenosine monophosphate-activated protein kinase and AKT activation in the heart.
Conclusions: Cardiomyocyte-specific loss of BRCA1 alters critical pathways of fatty acid and glucose metab-
olism, leading to an energy starved heart. BRCA1-based cell or gene therapy might serve as a novel target to
improve cardiac bioenergetics in patients with heart failure. (J Thorac Cardiovasc Surg 2013;146:702-9)Germline mutations in the tumor suppressor breast cancer 1,
early onset (BRCA1) gene are highly penetrant for an in-
creased risk of breast and ovarian cancer syndromes.1
BRCA1 functions as a key gatekeeper of genome stability,
with an established role in key cellular processes involved
in DNA damage repair, transcriptional regulation, ubiq-
uitination, cell cycle control, and cellular regeneration.2
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The Journal of Thoracic and Cardiovascular Surgkey gatekeepers of cardiac structure and function, particu-
larly in the setting of ischemic, genotoxic, or septic
stressors.3-5 Using a Cre-loxP system, we generated
BRCA1 and BRCA2 cardiomyocyte-specific (CM) knock-
out mice and demonstrated that experimental myocardial
infarction or genotoxic stress in the form of doxorubicin eli-
cited profound cardiac failure and death.3,4Mechanistically,
we demonstrated that decreased repair or accumulation
of damaged DNA led to increased cardiomyocyte
apoptosis by a p53-dependent pathway in these mice.3-5
These data suggest that BRCA1 might be a previously
unrecognized essential regulator of cardiac function and
that BRCA1-based therapies could serve as a novel thera-
peutic avenue for ischemic and genotoxic heart failure.
In addition to cardiomyocyte apoptosis, alterations in
cardiac energy and substrate metabolism play a critical
role in the development and eventual transition into cardiac
failure.6 Since it has been suggested that BRCA1 interacts
with acetyl-coenzyme A (CoA) carboxylase (ACC) and in-
hibits fatty acid synthesis in cancer cells,7 we hypothesized
that BRCA1 might, in addition to regulating apoptosis,
serve to regulate cardiac bioenergetics. In the present re-
port, we specifically evaluated the key molecules involved
in fatty acid and glucose metabolism in the heart and
provide evidence that BRCA1 deficiency results in
an energy-compromised myocardium, primarily throughery c September 2013
Abbreviations and Acronyms
ACC ¼ acetyl-coenzyme A carboxylase
AMPK ¼ 50-adenosine monophosphate-activated
protein kinase
ATP ¼ adenosine triphosphate
BRCA1 ¼ breast cancer 1, early onset
CoA ¼ coenzyme A
CPT1 ¼ carnitine palmitoyltransferase 1
GLUT ¼ glucose transporter
MCD ¼ malonyl-CoA decarboxylase
PGC1a ¼ peroxisome proliferator-activated
receptor-g coactivator 1a
PPARs ¼ peroxisome proliferator-activated
receptors
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Animal Studies
All animal procedures were performed in accordancewith the guidelines
of the Canadian Council on Animal Care and were approved by the
St. Michael’s Hospital Animal Care Committee. To directly elucidate the
role ofBRCA1oncardiac structure, function, and survival and to circumvent
the embryonic lethality associated with systemic loss of BRCA1,8 we ap-
plied the Cre-loxP system to disrupt BRCA1 expression specifically in the
cardiomyocytes.3 Conditional inactivation of BRCA1 in the cardiomyocytes
was achieved by crossing mice homozygous for the exon 11 floxed BRCA1
allele with hemizygous mice expressing Cre-recombinase under the control
of the a-myosin heavy chain promoter, which is predominantly expressed in
the adult cardiomyocyte.9 The mice, regardless of their genotypes, were vi-
able and fertile and were born in the expectedMendelian ratios. Analysis of
genomic DNA from the heart, brain, liver, and skeletal muscles revealed that
the Cre-mediated recombined allele was only present in the heart samples
and absent in the brain, liver, and skeletal muscles of CM-BRCA1þ/ and
CM-BRCA1/ mice. Successful deletion of BRCA1 at the protein level
was confirmed by Western blot and immunohistochemical analysis. Taken
together, these findings validate the successful generation of mice with
cardiomyocyte-specific inactivation of full-length BRCA1.3
RNA Measurements and Western Blotting
Total whole heart RNAwas reverse transcribed and real-time reactions
performed with a SYBR Green master mix on the PRISM 7900HT system
(both Life Technologies, Carlsbad, Calif).
The immunoblots were probed with antibodies from Cell Signaling
(Beverley, Mass) against ACC, phosphorylated ACC, AKT, phosphory-
lated AKT, 50-adenosine monophosphate-activated protein kinase
(AMPK), phosphorylated AMPK, and peroxisome proliferator-activated
receptor-g coactivator 1a (PGC1a) or from Chemicon (Billerica, Mass) di-
rected against glyceraldehyde 3-phosphate dehydrogenase. Immunoband
signals were visualized by enhanced chemiluminescence (GE Healthcare
Biosciences, Pittsburgh, Pa).
Fatty Acid and Glucose Metabolism
Ex vivo working mice hearts were aerobically perfused, as previously
described.10 The rates of glucose and palmitate oxidation were measuredThe Journal of Thoracic and Cadirectly from the production of 14CO2 and
3H2O from [U-
14C]glucose and
[9,10-3H]palmitate, respectively.10 The adenosine triphosphate (ATP)
yield was calculated using a stoichiometric ratio of 30 mol ATP/mol
glucose and 105 mol ATP/mol palmitate being oxidized.10 This
calculation assumes 100% coupling of mitochondrial oxidative
phosphorylation.
Statistical Analysis
Unless otherwise stated, the data are presented as the mean SD. Real-
time data were analyzed using the relative expression software tool. The
Student t test was applied when data from 2 groups were compared.
Differences between multiple groups were evaluated using analysis of
variance, with the Bonferroni correction.RESULTS
Cardiomyocyte-Specific Deletion of BRCA1 Reduces
Acetyl-CoA Carboxylase 2 and Malonyl-CoA
Decarboxylase Expression
In addition to being a critical regulator of the lipogenic
pathway, ACC is a key regulator of fatty acid oxidation
in the heart, secondary to catalyzing the carboxylation of
acetyl-CoA to form malonyl-CoA, a potent inhibitor of
mitochondrial fatty acid uptake.11,12 Compared with
their wild-type control littermates, CM-BRCA1/ and
CM-BRCA1þ/ mice demonstrated a significant reduction
in cardiac expression of ACC2, the predominant cardiac
variant of ACC, but not ACC1 (Figure 1, A and B). Total
ACC levels were indistinguishable between the groups
(data not shown). Malonyl-CoA decarboxylase (MCD)
acts to regulate malonyl-CoA levels through its decarbox-
ylation of malonyl-CoA back into acetyl-CoA, thereby
stimulating fatty acid oxidation.13 CM- BRCA1 loss
resulted in a reduction in cardiac MCD expression
(Figure 1, C).Cardiomyocyte-Specific Deletion of BRCA1 Alters
Peroxisome Proliferator-Activated Receptor
Signaling
The peroxisome proliferator-activated receptors (PPARs)
are a family of ligand-activated transcription factors within
the broad nuclear receptor superfamily.14 PPARa, a regula-
tor of myocardial lipid and energy metabolism, was signif-
icantly downregulated in the hearts of CM-BRCA1þ/ and
CM-BRCA1/ mice (Figure 2, A).15 However, PPARb
expression was similar across the groups (Figure 2, B). In
contrast, the levels of cardioprotective PPARg were also
significantly downregulated in BRCA1-deficient hearts
(Figure 2, C).
Differential regulation was observed in several impor-
tant downstream PPAR substrates. ACC2 and MCD are
regulated by PPARa, and both were downregulated in
the hearts of CM-BRCA1þ/ and CM-BRCA1/ mice
(Figure 1, B and C), as was the membrane-associated
88-kDa fatty acid translocase CD36, a mediator of car-
diac fatty acid uptake (Figure 3, A).16 Glucose transporterrdiovascular Surgery c Volume 146, Number 3 703
FIGURE 1. Cardiomyocyte-specific (CM) deletion of the breast cancer 1,
early onset (BRCA1) gene reduces cardiac acetyl-coenzyme A carboxylase
(ACC)2 and malonyl-CoA decarboxylase (MCD) expression. Total RNA
and protein were extracted from the hearts of 32-week-old female
CM-BRCA1þ/, CM-BRCA1/, and wild-type (WT) control littermates.
Real-time polymerase chain reaction was performed for A, ACC1, B,
ACC2 and C, MCD. n ¼ 3/group. *P<.05, **P<.01 versus WT.
FIGURE 2. Cardiomyocyte-specific (CM) deletion of the breast cancer 1,
early onset (BRCA1) gene alters peroxisome proliferator-activated receptor
(PPAR) signaling in the heart. Total RNAwas extracted from the hearts of
32-week-old female CM-BRCA1þ/, CM-BRCA1/, and wild-type (WT)
control littermates. Real-time polymerase chain reactionwas performed for
A, PPARa, B, PPARb, and C, PPARg. n ¼ 3/group. *P<.05, **P<.01
versus WT.
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the hearts of CM-BRCA1þ/ and CM-BRCA1/
mice (Figure 3, B and C). Carnitine palmitoyltransferase
1 (CPT1), a PPAR-responsive gene and the rate-limiting
enzyme in the mitochondrial uptake of free fatty acids,
was also downregulated in BRCA1-deficient hearts
(Figure 3, D).17704 The Journal of Thoracic and Cardiovascular SurgCardiomyocyte-Specific Deletion of BRCA1
Activates AMPK and AKT and Reduces PPAR
Coactivator-1a Expression
Activation of AMPK, a stress response triggering myo-
cardial glucose uptake and glycolysis, in addition to phos-
phorylating ACC and increasing fatty acid oxidation,ery c September 2013
FIGURE 3. Cardiomyocyte (CM)-specific deletion of the breast
cancer 1, early onset (BRCA1) gene reduces induction of peroxisome
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CM-BRCA1/ mice (Figure 4, A).18 Similarly, consistent
with its role in metabolic stress responses, phosphorylated
AKT levels were increased (Figure 4, B). In contrast, the
levels of PGC1a, a master activator of mitochondrial bio-
genesis that is reduced in failing hearts,19 were reduced in
the hearts of the CM-BRCA1þ/ and CM-BRCA1/
mice (Figure 4, C).Cardiomyocyte-Specific Deletion of BRCA1 Reduces
Glucose and Fatty Acid Oxidation Rates and ATP
Production in the Heart
The glucose oxidation and palmitate oxidation rates in
mouse hearts perfused in the working mode were measured,
and the ATP production rates from these 2 pathways were
calculated (Figure 5). Glucose oxidation (Figure 5, A) and
fatty acid oxidation (Figure 5, B) were significantly sup-
pressed in hearts from the more clinically relevant
BRCA1-haploinsufficient CM-BRCA1þ/ mice than in
the hearts from the wild-type control littermates. This re-
sulted in a significant decrease in the ATP production rates
from glucose and palmitate oxidation in BRCA1-deficient
hearts compared with the hearts of wild-type control litter-
mates (Figure 5, C).DISCUSSION
The heart has a very high energy demand, and alterations
in cardiac energy production contribute to the severity of is-
chemic injury and the development of heart failure.20 We
have previously demonstrated a cardioprotective role of
BRCA1/2 in response to ischemic and genotoxic stresses.3,4
Although we had proposed that the primary protective
mechanism through which BRCA1 acts involves DNA
damage repair and the prevention of cardiomyocyte
apoptosis, our present results suggest that BRCA1 might
also play an important role in regulating cardiac energy
and substrate metabolism. Accordingly, we suggest that
a loss of BRCA1 leads to a reduction in the cardiac
energy supply, with downregulation of both fatty acid
and glucose metabolic pathways and mitochondrial
bioenergetics.
BRCA1 is a critical molecule of inherited breast and
ovarian cancer syndromes. The tumor metabolic microenvi-
ronment is described by theWarburg phenomenon, the pref-
erential shift to glycolysis from glucose oxidation, even inproliferator-activated receptor (PPAR) targets in the heart. Total RNA
was extracted from the hearts of 32-week-old female CM-BRCA1þ/,
CM-BRCA1/, and wild-type (WT) control littermates. Real-time poly-
merase chain reaction was performed for A, CD36, B, glucose transporter
(GLUT)-4, C, GLUT-1, and D, carnitine palmitoyltransferase 1 (CPT1).
n ¼ 3/group. *P<.05, **P<.01 versus WT.
rdiovascular Surgery c Volume 146, Number 3 705
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FIGURE 4. Cardiomyocyte-specific (CM) deletion of the breast cancer 1,
early onset (BRCA1) gene activates cardiac 50-adenosine monophosphate-
activated protein kinase (AMPK) and AKT, while reducing peroxisome
proliferator-activated receptor-g coactivator 1a (PGC1a) expression. Total
protein was extracted from the hearts of 32-week-old female CM-
BRCA1þ/, CM-BRCA1/, and wild-type (WT) control littermates.
Western blots were performed and quantified for A, total and phosphory-
lated 50-adenosine monophosphate-activated protein kinase (AMPK),
=
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fatty acid synthesis.21 The BRCA1 C-terminal domain di-
rectly binds and sequesters ACC1.21 Hence, mutations in
BRCA1 disrupt the BRCA1–ACC1 complex, freeing
ACC1, which results in unregulated fatty acid synthesis, es-
sential for breast cancer proliferation.21 However, the broad
distribution of BRCA1 in tissues, including cardiac tissue,
suggests important roles for BRCA1-metabolic regulation
outside of tumor inhibition.3
Cardiac metabolism of fatty acid and carbohydrates is
finely regulated to provide a continuous source of energy
in the form of ATP, necessary to sustain contractile activity
and other cellular functions.6,22 Alterations in cardiac
bioenergetics have been associated with human and
experimental cardiac pathologic states.6,23,24 In ischemic
hearts, glucose oxidation and glycolysis are uncoupled,
and fatty acid metabolism predominates, resulting in
impaired functional recovery, progressive ventricular
remodeling, and eventual cardiac failure.24 We found in
BRCA1-deficient hearts, downregulation of enzymes that
control both glucose and fatty acid oxidation, instead of
a shift from one to the other. Substrate transporters within
the sarcolemma are a key regulatory component of myocar-
dial glucose and fatty acid use,25 and we found downregu-
lation of both the glucose transporter GLUT-4 and the
fatty acid transporter CD36 in BRCA1-deficient hearts. In
BRCA1-deficient hearts, MCD (which degrades malonyl-
CoA, an inhibitor of CPT1), was also downregulated, block-
ing fatty acid oxidation.13 The PPARa-responsive gene
CPT1, a rate-limiting enzyme in the mitochondrial uptake
of fatty acids, was also downregulated.17,26 The combined
decrease in CD36, MCD, and CPT1 expression could all
potentially contribute to the decrease in fatty acid
oxidation observed in the BRCA1-deficient hearts.
An important finding in the present work was the decrease
in PPARs, a family of ligand-activated transcription factors
within the broad nuclear receptor superfamily. PPARa,
abundant in tissues with high rates of mitochondrial fatty
acid oxidation, such asmyocardial tissue, regulates the target
genes involved in cellular lipid catabolism.15 In contrast,
PPARg directs the expression of genes involved in fat stor-
age, and recent studies have suggested that PPARg agonists
are cardioprotective against an ischemic insult.27,28 We
report significant downregulation of PPARa and PPARg in
BRCA1-deficient hearts. This suggests dysregulation of
both glucose and fatty acid oxidation. We observed coinci-
dent downregulation of CD36, the PPAR-responsive mem-
brane-associated 88-kDa fatty acid translocase that
controls cardiac fatty acid uptake and GLUT-4.29,30B, total and phosphorylated AKT, and C, PGC1a. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used as a loading control.
n ¼ 3-4/group. *P<.05 versus WT.
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FIGURE 5. Cardiomyocyte-specific (CM) deletion of the breast cancer 1,
early onset (BRCA1) gene reduces rates of glucose and fatty acid oxidation
and adenosine triphosphate (ATP) production in the heart. Rates of A, glu-
cose oxidation, B, palmitate oxidation and C, ATP production were deter-
mined in the aerobic hearts of CM-BRCA1þ/ and wild-type (WT) control
littermates ex vivo. n ¼ 4-6/group. *P<.05, **P<.01 versus WT.
FIGURE 6. Proposed mechanism for breast cancer 1, early onset
(BRCA1) gene–mediated metabolic regulation. Fatty acid and glucose
transporters are reduced in BRCA1-deficient cardiomyocytes, leading to
reduced b-oxidation and glucose oxidation. Acetyl-coenzymeA (CoA) car-
boxylase (ACC) carboxylates acetyl-CoA into malonyl-CoA, and malonyl-
CoA decarboxylase (MCD) decarboxylates malonyl-CoA back into acetyl-
CoA. MCD is reduced in BRCA1-deficient cardiomyocytes, causing
malonyl-CoA to accumulate, which in turn leads to inhibitedmitochondrial
uptake of fatty acids through carnitine palmitoyltransferase 1 (CPT1).
CPT1 levels, which are also reduced in BRCA1-deficient cardiomyocytes,
result in inhibition of b-oxidation rates. 50-Adenosine monophosphate-
activated protein kinase (AMPK) phosphorylation negatively regulates
ACC, and mitochondrial biogenesis is reduced owing to decreases in
PGC1a levels. In brief, cardiomyocyte-specific loss of BRCA1 results in
reduced expression of fatty acid and glucose transporters, reduced levels
of downstream mediators of fatty acid and glucose oxidation, and reduced
mitochondrial biogenesis, leading to an energy starved heart and eventually
culminating in heart failure. All downregulated and upregulated molecules
are shown by red and green arrows, respectively. FFA, Free fatty acid.
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which promotes glucose uptake and glycolysis and fatty
acid oxidation, was upregulated in BRCA1-deficient hearts.
AMPK is triggered by cardiac ischemia,31 and the increase
in AMPK levels might have resulted from attempts to in-
crease energy supply. This is consistent with experimental
severe end-stage heart failure, demonstrating depression
in the overall oxidative metabolism, with a preserved ratio
between fatty acid and glucose oxidation.32 AKT, which
promotes glucose oxidation by enhancing glucose uptake
through glucose transporters and attenuates fatty acid oxi-
dation through downregulation of PPARa and PGC1a,
was also upregulated in BRCA1-deficient hearts, which
again might have been an attempted compensator response
to the metabolic stress in these hearts.18
The rates of flux through metabolic pathways are con-
trolled by the extent of expression of key metabolicrdiovascular Surgery c Volume 146, Number 3 707
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abolic pathway regulation.6 The reduced levels of fatty acid
and glucose transporters in BRCA1-deficient cardiomyo-
cytes were associated with less b-oxidation and glucose
oxidation. Significantly reduced ATP production rates
were also noted in BRCA1-deficient hearts. We therefore
propose that BRCA1 regulates metabolic control by the
schema illustrated in Figure 6. ACC carboxylates acetyl-
CoA into malonyl-CoA and MCD decarboxylates
malonyl-CoA back into acetyl-CoA. MCD is reduced in
BRCA1-deficient cardiomyocytes, causing malonyl-CoA
to accumulate, which in turn leads to inhibited mitochon-
drial uptake of fatty acids through CPT1. CPT1 levels,
which are also reduced in BRCA1-deficient cardiomyo-
cytes, result in inhibition of b-oxidation rates. Also,
AMPK phosphorylation negatively regulates ACC, and mi-
tochondrial biogenesis is reduced owing to decreases in
PGC1a levels. In brief, cardiomyocyte-specific loss of
BRCA1 results in the reduced expression of fatty acid and
glucose transporters, reduced levels of downstream media-
tors of fatty acid and glucose oxidation, and reduced mito-
chondrial biogenesis, leading to an energy starved heart,
eventually culminating in heart failure.
Using a lentivirus system,Niwano and colleagues33 devel-
oped a sarcoplasmic/endoplasmic reticulum Ca2þ-ATPase 2
gene transfer system and successfully demonstrated
integration of the sarcoplasmic/endoplasmic reticulum
Ca2þ-ATPase 2 gene into the rat heart, which resulted in ben-
eficial cardiac remodeling, function, and survival outcomes
after induction of myocardial infarction-associated heart
failure.33 Recently, investigators of the phase 2 CalciumUp-
regulation by PercutaneousAdministration of Gene Therapy
in Cardiac Disease study reported that patients with ad-
vanced heart failure who received intracoronary sarcoplas-
mic/endoplasmic reticulum Ca2þ-ATPase 2a gene therapy
based on an adeno-associated virus 1 system exhibited either
improved or stabilized heart failure symptoms, exercise
tolerance, serum biomarker levels, and left ventricular func-
tion.34 These studies, although preliminary, are encouraging
and by no means minor advancements in the field. Future
studies aimed at using direct intramyocardial delivery of
adenoviral, adeno-associated virus, or lentiviral gene deliv-
ery approaches in larger animal models (eg, porcine) could
be envisioned. BRCA1 might represent a novel platform
for cell-based approaches to myocardial regeneration,
and BRCA1-overexpressing bone marrow cells, myoblasts,
or progenitor cells might provide an alternative cell
therapy mode.
The present study had a few limitations. Although we
have previously demonstrated impaired left ventricular
systolic function and increased mortality rates in
CM-BRCA1-deficient mice in response to ischemic and
genotoxic stressors, the present study would have been
strengthened if the glucose oxidation and fatty acid708 The Journal of Thoracic and Cardiovascular Surgoxidation rates were measured simultaneous as a function
of generated cardiac power or dP/dT was measured using,
for example, a Langendorff preparation. However, we did
assess the rates of glucose oxidation and palmitate oxida-
tion in mouse hearts perfused in the ‘‘working heart
mode,’’ and the ATP production rates from these 2 pathways
were calculated. We also acknowledge that the study would
have been improved further by a gain of function approach
using either viral delivery of BRCA1 or cell-based therapy
to determine whether function and metabolism could be
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